These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

673 related items for PubMed ID: 10462247

  • 1. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
    Robin G, Keisari Y, Slepon R, Ashkenazi S, Cohen D.
    Vaccine; 1999 Aug 06; 17(23-24):3109-15. PubMed ID: 10462247
    [Abstract] [Full Text] [Related]

  • 2. Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.
    Cohen D, Orr N, Robin G, Slepon R, Ashkenazi S, Ashkenazi I, Shemer J.
    Clin Diagn Lab Immunol; 1996 Jul 06; 3(4):451-5. PubMed ID: 8807212
    [Abstract] [Full Text] [Related]

  • 3. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
    Passwell JH, Ashkenazi S, Harlev E, Miron D, Ramon R, Farzam N, Lerner-Geva L, Levi Y, Chu C, Shiloach J, Robbins JB, Schneerson R, Israel Shigella Study Group.
    Pediatr Infect Dis J; 2003 Aug 06; 22(8):701-6. PubMed ID: 12913770
    [Abstract] [Full Text] [Related]

  • 4. Characterization and quantitative analysis of serum IgG class and subclass response to Shigella sonnei and Shigella flexneri 2a lipopolysaccharide following natural Shigella infection.
    Robin G, Cohen D, Orr N, Markus I, Slepon R, Ashkenazi S, Keisari Y.
    J Infect Dis; 1997 May 06; 175(5):1128-33. PubMed ID: 9129076
    [Abstract] [Full Text] [Related]

  • 5. Shigella-specific antibodies in the first year of life among Zambian infants: A longitudinal cohort study.
    Chisenga CC, Bosomprah S, Simuyandi M, Mwila-Kazimbaya K, Chilyabanyama ON, Laban NM, Bialik A, Asato V, Meron-Sudai S, Frankel G, Cohen D, Chilengi R.
    PLoS One; 2021 May 06; 16(5):e0252222. PubMed ID: 34043697
    [Abstract] [Full Text] [Related]

  • 6. Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers.
    Cohen D, Ashkenazi S, Green M, Lerman Y, Slepon R, Robin G, Orr N, Taylor DN, Sadoff JC, Chu C, Shiloach J, Schneerson R, Robbins JB.
    Infect Immun; 1996 Oct 06; 64(10):4074-7. PubMed ID: 8926071
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids.
    Taylor DN, Trofa AC, Sadoff J, Chu C, Bryla D, Shiloach J, Cohen D, Ashkenazi S, Lerman Y, Egan W.
    Infect Immun; 1993 Sep 06; 61(9):3678-87. PubMed ID: 8359890
    [Abstract] [Full Text] [Related]

  • 11. Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.
    Riddle MS, Kaminski RW, Di Paolo C, Porter CK, Gutierrez RL, Clarkson KA, Weerts HE, Duplessis C, Castellano A, Alaimo C, Paolino K, Gormley R, Gambillara Fonck V.
    Clin Vaccine Immunol; 2016 Dec 06; 23(12):908-917. PubMed ID: 27581434
    [Abstract] [Full Text] [Related]

  • 12. Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice.
    Farzam N, Ramon-Saraf R, Banet-Levi Y, Lerner-Geva L, Ashkenazi S, Kubler-Kielb J, Vinogradov E, Robbins JB, Schneerson R.
    Vaccine; 2017 Sep 05; 35(37):4990-4996. PubMed ID: 28797729
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children.
    Passwell JH, Ashkenazi S, Banet-Levi Y, Ramon-Saraf R, Farzam N, Lerner-Geva L, Even-Nir H, Yerushalmi B, Chu C, Shiloach J, Robbins JB, Schneerson R, Israeli Shigella Study Group.
    Vaccine; 2010 Mar 02; 28(10):2231-2235. PubMed ID: 20056180
    [Abstract] [Full Text] [Related]

  • 16. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
    Oaks EV, Turbyfill KR.
    Vaccine; 2006 Mar 20; 24(13):2290-301. PubMed ID: 16364513
    [Abstract] [Full Text] [Related]

  • 17. Serum antibody responses against shigella lipopolysaccharides and invasion plasmid-coded antigens in shigella infected Swedish patients.
    Li A, Rong ZC, Ekwall E, Forsum U, Lindberg AA.
    Scand J Infect Dis; 1993 Mar 20; 25(5):569-77. PubMed ID: 8284641
    [Abstract] [Full Text] [Related]

  • 18. Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.
    Talaat KR, Alaimo C, Martin P, Bourgeois AL, Dreyer AM, Kaminski RW, Porter CK, Chakraborty S, Clarkson KA, Brubaker J, Elwood D, Frölich R, DeNearing B, Weerts H, Feijoo BL, Halpern J, Sack D, Riddle MS, Fonck VG.
    EBioMedicine; 2021 Apr 20; 66():103310. PubMed ID: 33862589
    [Abstract] [Full Text] [Related]

  • 19. Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge.
    Kelly M, Janardhanan J, Wagh C, Verma S, Charles RC, Leung DT, Kamruzzaman M, Pansuriya RK, Chowdhury F, Vann WF, Kaminski RW, Khan AI, Bhuiyan TR, Qadri F, Kováč P, Xu P, Ryan ET.
    Vaccine; 2024 Oct 24; 42(24):126263. PubMed ID: 39217775
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.